| Molly Mae Warthan, MD | |
|
5751 Edwards Ranch Rd Ste 101, Fort Worth, TX 76109-4131 | |
| (817) 923-8220 | |
| (817) 923-9004 |
| Full Name | Molly Mae Warthan |
|---|---|
| Gender | Female |
| Speciality | Dermatology |
| Experience | 20 Years |
| Location | 5751 Edwards Ranch Rd Ste 101, Fort Worth, Texas |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1073773867 | NPI | - | NPPES |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Molly M Warthan Md | 7810203817 | 5 |
| Warthan Dermatology Nacogdoches Pllc | 9638582844 | 4 |
News Archive
In a landmark drug-comparison study, Cleveland Clinic researchers found that bevacizumab (Avastin) is equivalent to ranibizumab (Lucentis) in the treatment of wet age-related macular degeneration (AMD) through two years.
UCLA/VA scientists have identified a new gene that controls how the body produces and uses fat. Called lipin, the gene may provide a new target for therapies to control obesity, diabetes and other weight-related disorders. The first issue of the new journal Cell Metabolism publishes the findings in its January 2005 edition.
An analysis published in Psychotherapy and Psychosomatics indicates the value of the Patient Health Questionnaire-9 for screening depression.
Diffusion Pharmaceuticals LLC, a clinical-stage drug-development company commercializing first-in-class drugs to treat serious or life-threatening unmet medical conditions, today announced that it closed on $5.9 million in additional private financing during the second half of 2009, bringing the total the company raised in 2009 to $7.1 million.
Throughout the past year, studies on the positive effects of weight loss surgery have been published in a variety of medical journals in the US and abroad. We learned that weight loss surgery is relatively safe, and that it is effective in improving serious health conditions. More recently, we also learned that it is a factor in preventing Type 2 diabetes from developing in people considered to be pre-diabetic.
› Verified 4 days ago
| Entity Name | Travis L Warthan |
|---|---|
| Entity Type | Practitioner - Dermatology |
| Entity Identifiers | NPI Number: 1679647317 PECOS PAC ID: 0648395897 Enrollment ID: I20100913000361 |
News Archive
In a landmark drug-comparison study, Cleveland Clinic researchers found that bevacizumab (Avastin) is equivalent to ranibizumab (Lucentis) in the treatment of wet age-related macular degeneration (AMD) through two years.
UCLA/VA scientists have identified a new gene that controls how the body produces and uses fat. Called lipin, the gene may provide a new target for therapies to control obesity, diabetes and other weight-related disorders. The first issue of the new journal Cell Metabolism publishes the findings in its January 2005 edition.
An analysis published in Psychotherapy and Psychosomatics indicates the value of the Patient Health Questionnaire-9 for screening depression.
Diffusion Pharmaceuticals LLC, a clinical-stage drug-development company commercializing first-in-class drugs to treat serious or life-threatening unmet medical conditions, today announced that it closed on $5.9 million in additional private financing during the second half of 2009, bringing the total the company raised in 2009 to $7.1 million.
Throughout the past year, studies on the positive effects of weight loss surgery have been published in a variety of medical journals in the US and abroad. We learned that weight loss surgery is relatively safe, and that it is effective in improving serious health conditions. More recently, we also learned that it is a factor in preventing Type 2 diabetes from developing in people considered to be pre-diabetic.
› Verified 4 days ago
| Entity Name | Molly M Warthan Md |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1306228432 PECOS PAC ID: 7810203817 Enrollment ID: O20150908001019 |
News Archive
In a landmark drug-comparison study, Cleveland Clinic researchers found that bevacizumab (Avastin) is equivalent to ranibizumab (Lucentis) in the treatment of wet age-related macular degeneration (AMD) through two years.
UCLA/VA scientists have identified a new gene that controls how the body produces and uses fat. Called lipin, the gene may provide a new target for therapies to control obesity, diabetes and other weight-related disorders. The first issue of the new journal Cell Metabolism publishes the findings in its January 2005 edition.
An analysis published in Psychotherapy and Psychosomatics indicates the value of the Patient Health Questionnaire-9 for screening depression.
Diffusion Pharmaceuticals LLC, a clinical-stage drug-development company commercializing first-in-class drugs to treat serious or life-threatening unmet medical conditions, today announced that it closed on $5.9 million in additional private financing during the second half of 2009, bringing the total the company raised in 2009 to $7.1 million.
Throughout the past year, studies on the positive effects of weight loss surgery have been published in a variety of medical journals in the US and abroad. We learned that weight loss surgery is relatively safe, and that it is effective in improving serious health conditions. More recently, we also learned that it is a factor in preventing Type 2 diabetes from developing in people considered to be pre-diabetic.
› Verified 4 days ago
| Entity Name | Warthan Dermatology Nacogdoches Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1144820135 PECOS PAC ID: 9638582844 Enrollment ID: O20210107001968 |
News Archive
In a landmark drug-comparison study, Cleveland Clinic researchers found that bevacizumab (Avastin) is equivalent to ranibizumab (Lucentis) in the treatment of wet age-related macular degeneration (AMD) through two years.
UCLA/VA scientists have identified a new gene that controls how the body produces and uses fat. Called lipin, the gene may provide a new target for therapies to control obesity, diabetes and other weight-related disorders. The first issue of the new journal Cell Metabolism publishes the findings in its January 2005 edition.
An analysis published in Psychotherapy and Psychosomatics indicates the value of the Patient Health Questionnaire-9 for screening depression.
Diffusion Pharmaceuticals LLC, a clinical-stage drug-development company commercializing first-in-class drugs to treat serious or life-threatening unmet medical conditions, today announced that it closed on $5.9 million in additional private financing during the second half of 2009, bringing the total the company raised in 2009 to $7.1 million.
Throughout the past year, studies on the positive effects of weight loss surgery have been published in a variety of medical journals in the US and abroad. We learned that weight loss surgery is relatively safe, and that it is effective in improving serious health conditions. More recently, we also learned that it is a factor in preventing Type 2 diabetes from developing in people considered to be pre-diabetic.
› Verified 4 days ago
| Entity Name | Warthan Dermatology Dallas Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1598548257 PECOS PAC ID: 9931554839 Enrollment ID: O20231012002876 |
News Archive
In a landmark drug-comparison study, Cleveland Clinic researchers found that bevacizumab (Avastin) is equivalent to ranibizumab (Lucentis) in the treatment of wet age-related macular degeneration (AMD) through two years.
UCLA/VA scientists have identified a new gene that controls how the body produces and uses fat. Called lipin, the gene may provide a new target for therapies to control obesity, diabetes and other weight-related disorders. The first issue of the new journal Cell Metabolism publishes the findings in its January 2005 edition.
An analysis published in Psychotherapy and Psychosomatics indicates the value of the Patient Health Questionnaire-9 for screening depression.
Diffusion Pharmaceuticals LLC, a clinical-stage drug-development company commercializing first-in-class drugs to treat serious or life-threatening unmet medical conditions, today announced that it closed on $5.9 million in additional private financing during the second half of 2009, bringing the total the company raised in 2009 to $7.1 million.
Throughout the past year, studies on the positive effects of weight loss surgery have been published in a variety of medical journals in the US and abroad. We learned that weight loss surgery is relatively safe, and that it is effective in improving serious health conditions. More recently, we also learned that it is a factor in preventing Type 2 diabetes from developing in people considered to be pre-diabetic.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Molly Mae Warthan, MD 5751 Edwards Ranch Rd Ste 101, Fort Worth, TX 76109-4131 Ph: (817) 923-8220 | Molly Mae Warthan, MD 5751 Edwards Ranch Rd Ste 101, Fort Worth, TX 76109-4131 Ph: (817) 923-8220 |
News Archive
In a landmark drug-comparison study, Cleveland Clinic researchers found that bevacizumab (Avastin) is equivalent to ranibizumab (Lucentis) in the treatment of wet age-related macular degeneration (AMD) through two years.
UCLA/VA scientists have identified a new gene that controls how the body produces and uses fat. Called lipin, the gene may provide a new target for therapies to control obesity, diabetes and other weight-related disorders. The first issue of the new journal Cell Metabolism publishes the findings in its January 2005 edition.
An analysis published in Psychotherapy and Psychosomatics indicates the value of the Patient Health Questionnaire-9 for screening depression.
Diffusion Pharmaceuticals LLC, a clinical-stage drug-development company commercializing first-in-class drugs to treat serious or life-threatening unmet medical conditions, today announced that it closed on $5.9 million in additional private financing during the second half of 2009, bringing the total the company raised in 2009 to $7.1 million.
Throughout the past year, studies on the positive effects of weight loss surgery have been published in a variety of medical journals in the US and abroad. We learned that weight loss surgery is relatively safe, and that it is effective in improving serious health conditions. More recently, we also learned that it is a factor in preventing Type 2 diabetes from developing in people considered to be pre-diabetic.
› Verified 4 days ago
Diego Esteban Marra, MD Dermatology Medicare: Accepting Medicare Assignments Practice Location: 2801 S Hulen St Ste 400, Fort Worth, TX 76109 Phone: 817-921-2838 | |
Dr. Allison Beckworth Readinger, M.D. Dermatology Medicare: Accepting Medicare Assignments Practice Location: 800 8th Ave Ste 326, Fort Worth, TX 76104 Phone: 817-885-8222 Fax: 817-885-8663 | |
Kimberly J Parham, MD Dermatology Medicare: Not Enrolled in Medicare Practice Location: 6600 Bryant Irvin Rd, Fort Worth, TX 76132 Phone: 817-820-0011 Fax: 817-820-0073 | |
Dr. Stephen D Maberry, MD Dermatology Medicare: Accepting Medicare Assignments Practice Location: 1200 W Rosedale St, Fort Worth, TX 76104 Phone: 817-336-8131 | |
Dr. James Richmond Mccarty, M.D. Dermatology Medicare: Accepting Medicare Assignments Practice Location: 4305 S Hulen St, Fort Worth, TX 76109 Phone: 817-920-9023 Fax: 817-923-6013 | |
Bryan J Carroll, M.D. Dermatology Medicare: Accepting Medicare Assignments Practice Location: 6900 Harris Pkwy Ste 200, Fort Worth, TX 76132 Phone: 817-292-3376 Fax: 844-886-8347 |